Cresset and Optibrium announce technology collaboration


Combines methods for the design of new drug discovery compounds

Cresset and Optibrium, UK providers of software solutions for drug discovery, are to work together, combining software to help drug discovery projects identify novel, potent compounds with a high chance of success downstream.

The collaboration will involve a two-way exchange of technologies: Optibriumís ADME models, currently provided as a plug-in module for its StarDrop software, will be made available to users of Cressetís desktop applications, while Cressetís FieldAlign software, which helps chemists understand the 3D structure-activity-relationship of their chemistry, will be made available as an optional plug-in module for StarDrop.

Welwyn Garden City based Cressetís molecular field technology provides unique insight into the biological activity, properties and interactions of molecules, which enables biologically meaningful comparisons that are not limited by two-dimensional structure. Optibriumís StarDrop platform helps to guide decisions on the design and selection of compounds by integrating in silico and experimentally measured properties using a multi-parameter optimisation approach, chemical space and Glowing Molecule visualisations and predictive modelling.

Matthew Segall, ceo of Cambridge-based Optibrium, said: ĎThis collaboration furthers our aim to deliver leading edge in silico technologies directly to the desktop of all drug discovery scientists through StarDropís user friendly, interactive interface.

ĎThe new FieldAlign module in StarDrop will bring a powerful 3D view of compound interactions that will complement StarDropís existing 2D QSAR models.í

The technology shared under this collaboration will form new components in upcoming releases of Optibriumís StarDrop and Cressetís desktop applications. The firms say full details of these new developments will be announced shortly.

Email this story